))
Ep. 204: Exciting Updates from AAAAI 2024
Manage episode 404214686 series 3392202
Вміст надано FAACT's Roundtable Podcast. Весь вміст подкастів, включаючи епізоди, графіку та описи подкастів, завантажується та надається безпосередньо компанією FAACT's Roundtable Podcast або його партнером по платформі подкастів. Якщо ви вважаєте, що хтось використовує ваш захищений авторським правом твір без вашого дозволу, ви можете виконати процедуру, описану тут https://uk.player.fm/legal.
Learn about ground-breaking news and updates from the recent American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting held this February in Washington, D.C. In lay relatable terms, FAACT’s Medical Advisory Board Chair, Dr. Shahzad Mustafa, discusses the approval of Xolair and what it means for the food allergy community. He also shares his thoughts regarding treatments that are on-the-horizon for anaphylaxis from ARS Pharma, Bryn Pharma, Aquestive, DBV Technologies, and Blueprint Medicines.
Resources to keep you in the know:
- New England Journal of Medicine Publishes Phase III Data Showing Xolair Significantly Reduced Allergic Reactions Across Multiple Foods in People With Food Allergies (Genentech)
- ARS Pharma
- Bryn Pharma
- Aquestive
- DBV Technologies
- Blueprint Medicines
- Takeda (EOHILIA)
- FAACT's Resources:
You can also find FAACT’s Roundtable Podcast on Apple Podcast, Spotify, iHeart Radio, Podcast Chaser, Deezer, Tune-In, Alexa, and Listen Notes or wherever you listen to podcasts.
Follow us on Facebook, X (formerly known as Twitter), Instagram, Threads, LinkedIn, Pinterest, TikTok, and
Thanks for listening! FAACT invites you to discover more exciting food allergy resources at FoodAllergyAwareness.org!
207 епізодів
Поширити
